% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Acampora:819675,
author = {Acampora, Federica and Marzaioli, Alberto Maria and
Capuozzo, Antonella and Appavou, Marie-Sousai and
Campanella, Antonella and D'Errico, Gerardino and Irace,
Carlo and Montesarchio, Daniela and Musumeci, Domenica and
Szekely, Noemi and Santamaria, Rita and DeCastro, Cristina
and Paduano, Luigi},
title = {{L}ipooligosaccharides as {A}mphiphiles to {B}uild
{L}iposomes for {E}ffective {D}rug {D}elivery: {T}he {C}ase
of {A}nticancer {R}uthenium {C}omplex-{B}ased {A}ggregates},
journal = {ChemistrySelect},
volume = {1},
number = {10},
issn = {2365-6549},
address = {Weinheim},
publisher = {Wiley-VCH},
reportid = {FZJ-2016-05282},
pages = {2129 - 2139},
year = {2016},
abstract = {Liposomes are complex aggregates, often including
polyethylene glycol (PEG) to expand their life span
in vivo, although their full biocompatibility is still
questioned. With the aim to suitably replace PEG within
liposomal formulations, here we propose a new liposomes
formulation, which includes an amphiphilic molecule of
natural origin: the lipooligosaccharide (LOS) from the
Gram-negative bacterium Rhizobium rubi. LOS architecture is
bifunctional: the lipid moiety at one terminus promotes its
insertion into the liposome, the other terminus is
hydrophilic and in this case presents an oligosaccharide
motif similar to the human Lewis B antigen. Liposomes were
prepared by co-formulating de-O-acylated LOS (de-LOS) with
the lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) and the anticancer nucleolipid-based Ru(III) complex,
ToThyRu. In-depth microstructural characterization shows
that de-LOS containing liposomes are stable aggregates. In
vitro preliminary bioscreens have disclosed their negligible
toxic profile and a good uptake in MCF-7 and HaCaT cells.
The results validate the use of lipooligosaccharides in
formulating liposomes and pave the way to their use in drug
delivery applications.},
cin = {JCNS (München) ; Jülich Centre for Neutron Science JCNS
(München) ; JCNS-FRM-II / Neutronenstreuung ; JCNS-1},
ddc = {540},
cid = {I:(DE-Juel1)JCNS-FRM-II-20110218 /
I:(DE-Juel1)JCNS-1-20110106},
pnm = {6G15 - FRM II / MLZ (POF3-6G15) / 6G4 - Jülich Centre for
Neutron Research (JCNS) (POF3-623)},
pid = {G:(DE-HGF)POF3-6G15 / G:(DE-HGF)POF3-6G4},
experiment = {EXP:(DE-MLZ)KWS2-20140101},
typ = {PUB:(DE-HGF)16},
UT = {WOS:000395417800006},
doi = {10.1002/slct.201600255},
url = {https://juser.fz-juelich.de/record/819675},
}